David OMalley, Director for Translational & Clinical Research Partnerships, Leader, Clinical Trial Innovation at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn:
“Plain language summaries like this one are such a valuable resource, quick to reference and easy to use as schematics in presentations.
Congrats to an outstanding international group of collaborators on this plain language summary of the Phase II ENGOT-OV60/GOG-3052/RAMP 201 trial, evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.
The Ohio State University Wexner Medical Center and The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute helping lead the way in developing new therapies for this rare ovarian cancer subtype.”
Title: The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Authors: Susana Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro Santin, Premal Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen Moore, Stephanie Lustgarten, David O’Malley, Toon Van Gorp, Rachel Grisham
Read the Full Article on Future Oncology
More posts featuring David OMalley.